SAFETY, TOLERABILITY AND MECHANISM OF ACTION OF BOSWELLIC ACIDS (BA) IN MULTIPLE SCLEROSIS (MS) AND CLINICALLY ISOLATED SYNDROME (CIS): A MRI-CONTROLLED, MULTICENTER, BASELINE-TO-TREATMENT, 32-WEEKS, OPEN-LABEL, PHASE IIA TRIAL IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS OR CLINICALLY ISOLATED SYNDROME - SABA

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2010
This article has no abstract
Epistemonikos ID: cfdfa29ebe086c9db0e5f1396414dedfea260c6d
First added on: Apr 17, 2025